These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Tutorial in biostatistics: the self-controlled case series method. Whitaker HJ; Farrington CP; Spiessens B; Musonda P Stat Med; 2006 May; 25(10):1768-97. PubMed ID: 16220518 [TBL] [Abstract][Full Text] [Related]
24. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design. Xu S; Hambidge SJ; McClure DL; Daley MF; Glanz JM Stat Med; 2013 Aug; 32(19):3290-9. PubMed ID: 23303643 [TBL] [Abstract][Full Text] [Related]
25. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Belongia EA; Irving SA; Shui IM; Kulldorff M; Lewis E; Yin R; Lieu TA; Weintraub E; Yih WK; Li R; Baggs J; Pediatr Infect Dis J; 2010 Jan; 29(1):1-5. PubMed ID: 19907356 [TBL] [Abstract][Full Text] [Related]
26. More on RotaShield and intussusception: the role of age at the time of vaccination. Simonsen L; Viboud C; Elixhauser A; Taylor RJ; Kapikian AZ J Infect Dis; 2005 Sep; 192 Suppl 1():S36-43. PubMed ID: 16088803 [TBL] [Abstract][Full Text] [Related]
27. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. Takeuchi Y; Shinozaki T; Matsuyama Y BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575 [TBL] [Abstract][Full Text] [Related]
28. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America. Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803 [TBL] [Abstract][Full Text] [Related]
29. Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. Bravo L; Chitraka A; Liu A; Choudhury J; Kumar K; Berezo L; Cimafranca L; Chatterjee P; Garg P; Siriwardene P; Bernardo R; Mehta S; Balasubramanian S; Karkada N; Htay Han H Hum Vaccin Immunother; 2014; 10(8):2276-83. PubMed ID: 25424932 [TBL] [Abstract][Full Text] [Related]
30. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969 [TBL] [Abstract][Full Text] [Related]
31. Intussusception and rotavirus vaccination: a review of the available evidence. Patel MM; Haber P; Baggs J; Zuber P; Bines JE; Parashar UD Expert Rev Vaccines; 2009 Nov; 8(11):1555-64. PubMed ID: 19863248 [TBL] [Abstract][Full Text] [Related]
32. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080 [TBL] [Abstract][Full Text] [Related]
33. Evaluating the potential risks and benefits of infant rotavirus vaccination in England. Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524 [TBL] [Abstract][Full Text] [Related]
34. Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit Study. Yung CF; Chan SP; Soh S; Tan A; Thoon KC J Pediatr; 2015 Jul; 167(1):163-8.e1. PubMed ID: 25882872 [TBL] [Abstract][Full Text] [Related]
35. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants. Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138 [TBL] [Abstract][Full Text] [Related]